NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma
Latest Information Update: 07 Apr 2023
Price :
$35 *
At a glance
- Drugs Iobenguane (Primary) ; Cefixime; Irinotecan; Vincristine; Vorinostat
- Indications Neuroblastoma
- Focus Therapeutic Use
- Acronyms NANT2011-01
- 01 Apr 2023 Results asseesing Peripheral blood biomarkers relevant to radiation exposure demonstrate significant modulation after 131I-MIBG and concomitant radiation sensitizers affect extent of modulation, published in the International Journal of Radiation Oncology, Biology, Physics
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results (n=99) evaluating marker association with treatment arm, clinical response using NANT response criteria, toxicity, and whole-body radiation dose,presented at the 58th Annual Meeting of the American Society of Clinical Oncology.